Ambit Biosciences prices IPO at $8

Comment

Shutterstock photo

Ambit Biosciences, which is developing small molecule therapeutics for the treatment of acute myeloid leukemia, raised $65 million by offering 8.1 million shares at $8. Ambit Biosciences plans to list on the NASDAQ under the symbol AMBI. Ambit Biosciences initially filed confidentially on 12/20/2012. Citi and Leerink Swann acted as joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com